# Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects

> **NCT07246252** · PHASE1 · COMPLETED · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 114 (actual)

## Conditions studied

- Healthy Volunteers (HV)

## Interventions

- **BIOLOGICAL:** Process-Changed CMAB007
- **BIOLOGICAL:** Xolair (omalizumab)

## Key facts

- **NCT ID:** NCT07246252
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-28
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-02
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246252, "Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07246252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*